Nanomedicine –

§ April 14th, 2019 § Filed under Nano Medicine Comments Off on Nanomedicine –

Our nanomedicine research will focus on cancer disease. The Gallogly College of Engineering will work in close collaboration with the Peggy and Charles Stephenson Cancer Center.

I. Can Photothermal Therapy be Used Effectively to Treat Tumors that Have Been Targeted with Single-Walled Carbon Nanotubes?

Partnership Project Photothermal and Immunostimulation of Melanoma in collaboration with OU-HSC Department of Pathology.

Project Goal: To determine the effectiveness in a mouse model of a new therapy for cutaneous metastatic melanoma by targeting single-walled carbon nanotubes (SWNTs) to the tumor vasculature, combined with photothermal therapy and immunostimulation.

Partnership Project Photothermal Therapy of Bladder Cancer Using Targeted Single Walled Carbon Nanotubes in collaboration with OU-HSC Department of Urology.

Project Goal: To determine the effectiveness in a mouse model of treating non-muscle invasive bladder cancer by photothermal therapy after binding of SWNTs to the tumors.

II. Can nanoparticles targeted to the tumor vasculature be used for effective imaging of vascularized tumors?

New Exploratory Project Gold Nanoparticles Targeted to the Breast Tumor Vasculature for Imaging.

Project Goal: To functionalize gold nanoparticles for targeting the tumor vasculature. To validate the binding to cells grown in vitro that mimic the tumor vasculature. To test the functionalized nanoparticles for imaging breast tumors grown in mice.

III. Can Tissue Scaffolds with Controllable Architectural Features from Micro to Nano be Used to Image and Treat Metastasizing Cancer Cells?

New Exploratory Project Imaging and Treating Metastasizing Cancer Cells In Vitro in collaboration with OU-HSC Department of Cell Biology.

Project Goal: To develop 3D in vitro generated tissue systems for studying the metastasis of cancer cells to bone tissue, both for the purposes of imaging and treatment.

Read the original:
Nanomedicine -

Comments are closed.